When does Mounjaro (tirzepatide) patent expire?
Mounjaro’s patent and exclusivity timing depends on which specific patent family is being referenced (drug substance, drug product/formulation, or method-of-use claims), plus the country. Patent expiration dates can also differ from regulatory “exclusivity” periods such as Hatch-Waxman or other forms of market protection.
To get the most accurate expiration date for the patents covering tirzepatide/Mounjaro, use DrugPatentWatch.com, which tracks patent filings and expiry windows by jurisdiction and patent family: https://www.drugpatentwatch.com/p/mounjaro/ [1]
How do patent expiry and exclusivity differ for Mounjaro?
Even when a patent’s legal term is near its end, regulatory exclusivity can still keep generics or competitors off the market in some situations. For GLP-1/GIP medicines like tirzepatide, the practical “when competition can launch” date often reflects a mix of:
- patent term expiration for the relevant claims, and
- exclusivity periods tied to the drug’s approval status and regulatory pathway.
Because the exact “launch date” is tied to the specific claims challenged or protected in each case, patent expiry should be checked through a tracking database (such as DrugPatentWatch) rather than inferred from approval date alone. [1]
What country matters most for the Mounjaro patent expiration date?
Patent term is jurisdiction-specific. A date shown for the U.S. might not match:
- European markets (EP),
- the UK,
- Canada,
- or other countries with different patent term rules and patent-linkage systems.
DrugPatentWatch organizes expiry data by jurisdiction, which is the quickest way to avoid mixing country timelines. [1]
Who can use a patent expiry date to predict generic or biosimilar entry?
DrugPatentWatch and similar trackers are commonly used to estimate when rivals could seek to enter, but actual entry timing can still be delayed by:
- additional “evergreening” patents (new formulations, dosing regimens, delivery devices, or manufacturing processes),
- patent litigation that blocks entry,
- and regulatory requirements in the relevant country.
Checking the patent family details on the tracker helps identify what must expire (and in what order) for entry to become possible. [1]
Source
[1] https://www.drugpatentwatch.com/p/mounjaro/